Erasca (ERAS) Competitors

$10.46 +0.08 (+0.77%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$10.22 -0.24 (-2.25%)

As of 04:43 AM Eastern

ERAS vs. ELAN, AXSM, RDY, ARWR, and ABVX

Should you buy Erasca stock or one of its competitors? MarketBeat compares Erasca with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Erasca include Elanco Animal Health (ELAN), Axsome Therapeutics (AXSM), Dr. Reddy's Laboratories (RDY), Arrowhead Pharmaceuticals (ARWR), and Abivax (ABVX). These companies are all part of the "pharmaceutical products" industry.

How does Erasca compare to Elanco Animal Health?

Erasca (NASDAQ:ERAS) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

In the previous week, Erasca had 2 more articles in the media than Elanco Animal Health. MarketBeat recorded 16 mentions for Erasca and 14 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 0.54 beat Erasca's score of 0.16 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	2 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Elanco Animal Health	2 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

67.8% of Erasca shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 14.2% of Erasca shares are held by company insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Erasca currently has a consensus target price of $18.75, suggesting a potential upside of 79.25%. Elanco Animal Health has a consensus target price of $28.20, suggesting a potential upside of 29.14%. Given Erasca's higher possible upside, research analysts clearly believe Erasca is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Erasca has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A
Elanco Animal Health	$4.72B	2.31	-$232M	-$0.50	N/A

Erasca has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market.

Erasca has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-35.31%	-29.49%
Elanco Animal Health	-4.95%	7.42%	3.66%

Summary

Elanco Animal Health beats Erasca on 10 of the 16 factors compared between the two stocks.

How does Erasca compare to Axsome Therapeutics?

Erasca (NASDAQ:ERAS) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

In the previous week, Axsome Therapeutics had 5 more articles in the media than Erasca. MarketBeat recorded 21 mentions for Axsome Therapeutics and 16 mentions for Erasca. Erasca's average media sentiment score of 0.16 beat Axsome Therapeutics' score of -0.03 indicating that Erasca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	2 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Axsome Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

67.8% of Erasca shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 14.2% of Erasca shares are held by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Erasca currently has a consensus target price of $18.75, suggesting a potential upside of 79.25%. Axsome Therapeutics has a consensus target price of $251.26, suggesting a potential upside of 6.78%. Given Erasca's higher possible upside, research analysts clearly believe Erasca is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90

Erasca has higher earnings, but lower revenue than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A
Axsome Therapeutics	$638.50M	18.97	-$183.17M	-$3.73	N/A

Erasca has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market.

Erasca has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Erasca's return on equity of -35.31% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-35.31%	-29.49%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

Summary

Erasca and Axsome Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Erasca compare to Dr. Reddy's Laboratories?

Erasca (NASDAQ:ERAS) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

67.8% of Erasca shares are owned by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 14.2% of Erasca shares are owned by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Erasca currently has a consensus target price of $18.75, suggesting a potential upside of 79.25%. Dr. Reddy's Laboratories has a consensus target price of $16.90, suggesting a potential upside of 30.35%. Given Erasca's stronger consensus rating and higher probable upside, research analysts plainly believe Erasca is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Dr. Reddy's Laboratories has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A
Dr. Reddy's Laboratories	$3.58B	3.02	$663M	$0.77	16.84

Erasca has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market.

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Erasca's net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 12.28% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-35.31%	-29.49%
Dr. Reddy's Laboratories	12.90%	12.28%	8.25%

In the previous week, Erasca had 11 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 16 mentions for Erasca and 5 mentions for Dr. Reddy's Laboratories. Erasca's average media sentiment score of 0.16 beat Dr. Reddy's Laboratories' score of -0.58 indicating that Erasca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	2 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dr. Reddy's Laboratories	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

Erasca beats Dr. Reddy's Laboratories on 8 of the 15 factors compared between the two stocks.

How does Erasca compare to Arrowhead Pharmaceuticals?

Erasca (NASDAQ:ERAS) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

67.8% of Erasca shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 14.2% of Erasca shares are owned by company insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Erasca currently has a consensus target price of $18.75, suggesting a potential upside of 79.25%. Arrowhead Pharmaceuticals has a consensus target price of $87.80, suggesting a potential upside of 12.74%. Given Erasca's higher probable upside, research analysts plainly believe Erasca is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Arrowhead Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.83

Arrowhead Pharmaceuticals has higher revenue and earnings than Erasca. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A
Arrowhead Pharmaceuticals	$829.45M	13.23	-$1.63M	-$2.15	N/A

Erasca has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market.

Erasca has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Erasca's return on equity of -35.31% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-35.31%	-29.49%
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%

In the previous week, Arrowhead Pharmaceuticals had 5 more articles in the media than Erasca. MarketBeat recorded 21 mentions for Arrowhead Pharmaceuticals and 16 mentions for Erasca. Arrowhead Pharmaceuticals' average media sentiment score of 0.81 beat Erasca's score of 0.16 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	2 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arrowhead Pharmaceuticals	6 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Arrowhead Pharmaceuticals beats Erasca on 9 of the 16 factors compared between the two stocks.

How does Erasca compare to Abivax?

Erasca (NASDAQ:ERAS) and Abivax (NASDAQ:ABVX) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

In the previous week, Erasca had 9 more articles in the media than Abivax. MarketBeat recorded 16 mentions for Erasca and 7 mentions for Abivax. Abivax's average media sentiment score of 1.14 beat Erasca's score of 0.16 indicating that Abivax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	2 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Abivax	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Erasca has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, Abivax has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market.

67.8% of Erasca shares are owned by institutional investors. Comparatively, 47.9% of Abivax shares are owned by institutional investors. 14.2% of Erasca shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Erasca presently has a consensus price target of $18.75, indicating a potential upside of 79.25%. Abivax has a consensus price target of $137.15, indicating a potential upside of 12.50%. Given Erasca's higher probable upside, analysts clearly believe Erasca is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Abivax	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Erasca's return on equity of -35.31% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-35.31%	-29.49%
Abivax	N/A	-146.43%	-88.69%

Abivax is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A
Abivax	N/A	N/A	-$380.27M	-$5.37	N/A

Summary

Erasca beats Abivax on 9 of the 14 factors compared between the two stocks.

Get Erasca News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ERAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ERAS vs. The Competition

Export

Metric	Erasca	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.23B	$3.42B	$6.30B	$12.20B
Dividend Yield	N/A	2.30%	2.79%	5.30%
P/E Ratio	-11.25	18.67	21.03	25.58
Price / Sales	N/A	301.13	552.98	78.84
Price / Cash	N/A	122.51	42.94	55.34
Price / Book	8.24	6.75	9.82	6.66
Net Income	-$124.55M	$24.11M	$3.55B	$333.63M
7 Day Performance	0.58%	-0.53%	-0.53%	-0.11%
1 Month Performance	-41.40%	0.34%	1.20%	3.94%
1 Year Performance	723.62%	78.62%	41.23%	36.07%

Erasca Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ERAS Erasca	3.69 of 5 stars	$10.46 +0.8%	$18.75 +79.3%	+686.5%	$3.23B	N/A	N/A	120	Earnings Report Analyst Forecast
ELAN Elanco Animal Health	3.9197 of 5 stars	$23.54 -2.0%	$28.20 +19.8%	+67.2%	$11.99B	$4.72B	N/A	9,400	Analyst Downgrade
AXSM Axsome Therapeutics	2.4082 of 5 stars	$217.38 -1.3%	$251.26 +15.6%	+122.7%	$11.33B	$638.50M	N/A	380
RDY Dr. Reddy's Laboratories	3.2996 of 5 stars	$13.25 -1.3%	$16.90 +27.5%	-7.9%	$11.21B	$3.81B	17.21	27,811	News Coverage Earnings Report Analyst Downgrade Gap Up
ARWR Arrowhead Pharmaceuticals	2.2836 of 5 stars	$72.70 -6.7%	$84.90 +16.8%	+409.7%	$10.92B	$829.45M	N/A	400	Earnings Report Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ERAS) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Erasca (ERAS) Competitors

ERAS vs. ELAN, AXSM, RDY, ARWR, and ABVX

How does Erasca compare to Elanco Animal Health?

Summary

How does Erasca compare to Axsome Therapeutics?

Summary

How does Erasca compare to Dr. Reddy's Laboratories?

Summary

How does Erasca compare to Arrowhead Pharmaceuticals?

Summary

How does Erasca compare to Abivax?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERAS vs. The Competition

Erasca Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Erasca (ERAS) Competitors

ERAS vs. ELAN, AXSM, RDY, ARWR, and ABVX

How does Erasca compare to Elanco Animal Health?

Does the media favor ERAS or ELAN?

Do institutionals and insiders have more ownership in ERAS or ELAN?

Do analysts prefer ERAS or ELAN?

Which has stronger earnings & valuation, ERAS or ELAN?

Which has more volatility & risk, ERAS or ELAN?

Is ERAS or ELAN more profitable?

Summary

How does Erasca compare to Axsome Therapeutics?

Does the media favor ERAS or AXSM?

Do institutionals and insiders have more ownership in ERAS or AXSM?

Do analysts prefer ERAS or AXSM?

Which has stronger earnings & valuation, ERAS or AXSM?

Which has more volatility & risk, ERAS or AXSM?

Is ERAS or AXSM more profitable?

Summary

How does Erasca compare to Dr. Reddy's Laboratories?

Do insiders & institutionals believe in ERAS or RDY?

Do analysts recommend ERAS or RDY?

Which has higher earnings & valuation, ERAS or RDY?

Which has more risk and volatility, ERAS or RDY?

Is ERAS or RDY more profitable?

Does the media favor ERAS or RDY?

Summary

How does Erasca compare to Arrowhead Pharmaceuticals?

Do insiders & institutionals believe in ERAS or ARWR?

Do analysts recommend ERAS or ARWR?

Which has higher earnings & valuation, ERAS or ARWR?

Which has more risk and volatility, ERAS or ARWR?

Is ERAS or ARWR more profitable?

Does the media favor ERAS or ARWR?

Summary

How does Erasca compare to Abivax?

Does the media favor ERAS or ABVX?

Which has more volatility and risk, ERAS or ABVX?

Do institutionals and insiders have more ownership in ERAS or ABVX?

Do analysts rate ERAS or ABVX?

Is ERAS or ABVX more profitable?

Which has stronger earnings and valuation, ERAS or ABVX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERAS vs. The Competition

Erasca Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools